4523.T Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 Mai 2024 @ 07:52):

Stats
Tagesvolumen	754 900
Durchschnittsvolumen	1.43M
Marktkapitalisierung	1 878.37B
EPS	¥0 ( 2024-02-05 )
Nächstes Ertragsdatum	( ¥41.14 ) 2024-05-13
Last Dividend	¥80.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	41.29
ATR14	¥2.82 (0.04%)

Volumen Korrelation

Lang: 0.11 (neutral)

Kurz: -0.23 (neutral)

Signal:(45.046) Neutral

Eisai Co., Ltd. Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Eisai Co., Ltd. Korrelation - Währung/Rohstoff

-0.60
( weak negative )

-0.65
( moderate negative )

-0.39
( neutral )

-0.55
( weak negative )

0.65
( moderate )

Eisai Co., Ltd. Finanzdaten

Annual	2022
Umsatz:	¥744.40B
Bruttogewinn:	¥566.57B (76.11 %)
EPS:	¥193.31

FY	2022
Umsatz:	¥744.40B
Bruttogewinn:	¥566.57B (76.11 %)
EPS:	¥193.31

FY	2022
Umsatz:	¥756.23B
Bruttogewinn:	¥581.40B (76.88 %)
EPS:	¥669.08

FY	2021
Umsatz:	¥645.94B
Bruttogewinn:	¥484.63B (75.03 %)
EPS:	¥146.95

Financial Reports:

No articles found.

Eisai Co., Ltd. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥80.00 (N/A)	¥0 (N/A)	¥80.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Eisai Co., Ltd. Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.47 - Stable (9.32%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥11.50	2000-03-28
Last Dividend	¥80.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	48	--
Total Paid Out	¥2 807.50	--
Avg. Dividend % Per Year	0.00%	--
Score	3.8	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.47
Div. Directional Score	7.74	--

Next Divdend (Est)
(2024-07-03)

¥0 Estimate 1.26 %

Dividend Stability

0.10 Bad

Dividend Score

3.80

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8068.T	Ex Dividend Knight	2024-01-30	Semi-Annually	0.00%
7350.T	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%
6590.T	Ex Dividend Knight	2024-03-28	Annually	0.00%
5936.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
4617.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
3852.T	Ex Dividend Junior	2023-12-28	Annually	0.00%
3093.T	Ex Dividend Knight	2024-02-28	Semi-Annually	0.00%
1967.T	Ex Dividend Junior	2024-03-18	Annually	0.00%
9832.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
8897.T	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0606	1.500	8.79	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0346	1.200	8.85	10.00	[0 - 0.3]
returnOnEquityTTM	0.0546	1.500	-0.504	-0.756	[0.1 - 1]
payoutRatioTTM	1.011	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	2.38	0.800	3.10	2.48	[1 - 3]
quickRatioTTM	1.697	0.800	4.72	3.78	[0.8 - 2.5]
cashRatioTTM	1.025	1.500	5.42	8.12	[0.2 - 2]
debtRatioTTM	0.127	-1.500	7.89	-10.00	[0 - 0.6]
interestCoverageTTM	27.29	1.000	1.003	1.003	[3 - 30]
operatingCashFlowPerShareTTM	215.91	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	124.48	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.203	-1.500	9.19	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.789	1.000	0.176	0.176	[0.2 - 0.8]
operatingProfitMarginTTM	0.0851	1.000	-0.299	-0.299	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.372	1.000	9.04	9.04	[0.2 - 2]
assetTurnoverTTM	0.572	0.800	9.52	7.62	[0.5 - 2]
Total Score				10.02

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	41.56	1.000	5.90	0	[1 - 100]
returnOnEquityTTM	0.0546	2.50	-0.324	-0.756	[0.1 - 1.5]
freeCashFlowPerShareTTM	124.48	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	2.43	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	215.91	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	1.011	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	2.67	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0826	1.000	-0.434	0	[0.1 - 0.5]
Total Score				5.47

Eisai Co., Ltd.

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.